background image

M.D. Anderson Clinical Trials

Find clinical trials for M.D. Anderson. Search for M.D. Anderson clinical trials in different cities and states across the United States.

Filter
Active & Responsive

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

for
Ovarian Cancer, Fallopian Tube Cancer
Location: Boston MA, New York NY, Philadelphia PA, St Louis MO,
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT05287451

Recruiting
Active & Responsive

Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

for
Ovarian Cancer
Location: Providence RI, Morristown NJ, Rochester NY, Miami FL,
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 50 - 70+

Code: NCT00539162

Recruiting
Active & ResponsiveNew

Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

for
Hodgkin Lymphoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 2 - 21

Code: NCT07551583

Phase2, Recruiting
Active & ResponsiveNew

Pilot Study of Ivonescimab in Advanced/Metastatic Cutaneous Angiosarcoma

for
Cutaneous Angiosarcoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07655570

Phase2, Recruiting
Active & ResponsiveNew

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

for
Colorectal Cancer, Regorafenib, High Risk Patients
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07071961

Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & ResponsiveNew

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

for
Non-small Cell Lung Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07382726

Phase1, Recruiting
Active & ResponsiveNew

A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy

for
Phase 1b, Open Label, REC-617, RB1-Negative, Leiomyosarcoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07633756

Phase1, Recruiting
Active & ResponsiveNew

Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomized Controlled Trial (EHR Study #3)

for
Communication Skills, Professionalism,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07089953

Recruiting
Active & Responsive

Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions

for
Premalignant Lesion
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06561087

Phase2, Recruiting
Active & Responsive

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

for
Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06066424

Phase1, Recruiting